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SIGNIFICANCE
The German (PsoBest) and Swiss (SDNTT) Psoriasis Regist-
ries collect data on the efficacy of anti-psoriatic treatments 
among smokers and non-smokers. Out of 5,346 patients 
included in these registries, 1,264 met the inclusion cri-
teria for this study. In the smoking group, 715 (60.6%) 
reached therapy response at month 3, compared with 
358 (63.7%) in the non-smoking group. At month 6, 659 
(74.1%) vs. 330 (77%), and at month 12, 504 (76.6%) vs. 
272 (79.0%) reached therapy response. Therefore, these 
data do not show that smoking affects the response rate of 
anti-psoriatic therapy after 3, 6 and 12 months.
Psoriasis can involve the skin, joints, nails and cardio-
vascular system and result in a significant impairment 
in quality of life. Studies have shown a lower response 
rate to systemic anti-sporiatic therapies in smokers, 
and smoking is a trigger factor for psoriasis. The aim 
of this study was therefore to analyse the response to 
systemic therapies for psoriasis, with a focus on smo-
king. Prospectively collected data from patients with 
moderate to severe psoriasis included in the national 
psoriasis registries for Germany and Switzerland (Pso-
Best and SDNTT) were analysed. Therapy response was 
defined as reaching a Psoriasis Area and Severity Index 
(PASI) reduction of 75%, PASI ≤ 3 or Dermatology Life 
Quality Index (DLQI) ≤ 1. Out of 5,346 patients inclu-
ded in these registries, 1,264 met the inclusion crite-
ria for this study. In the smoking group, 715 (60.6%) 
reached therapy response at month 3, compared with 
358 (63.7%) in the non-smoking group (p ≤ 0.269), 
659 (74.1%) vs. 330 (77%) reached therapy respon-
se at month 6 (p ≤ 0.097), and 504 (76.6%) vs. 272 
(79.0%) at month 12 (p ≤ 0.611). Therefore, these data 
do not show that smoking affects the response rate of 
anti-psoriatic therapy after 3, 6 and 12 months.
Key words: tobacco; nicotine; psoriasis; fumaric acid esters; 
methotrexate; acitretin; ciclosporin; apremilast; adalimumab; 
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Smoking has been reported as a trigger factor for psoriasis (1) and smokers are at higher risk than non-
smokers of developing psoriasis (2). Among patients with 
psoriasis, the prevalence of cigarette smoking exceeds 
that of the general public (odds ratio (OR) 1.78) (2–5). 
Besides genetic factors, cigarette smoking and exposure 
to tobacco smoke in early childhood are associated with 
psoriasis, as shown in a retrospective study (6).
Triggering the onset of psoriasis can be mediated by 
genetic, inflammatory, or oxidative mechanisms (7). 
Smoking induces an elevated level of free radicals and 
thus causes oxidative damage (8). Several signalling 
pathways can be stimulated by tobacco use. Released 
cytokines activate T lymphocytes, which cause chronic 
inflammation (7). In addition, other triggering factors, 
such as obesity, oxidative stress and even insulin-
resistance, are aggravated by tobacco consumption (9). 
Both smoking and increased fat mass are associated with 
increased serum tumour necrosis factor (TNF)-α levels 
(10, 11). Furthermore, due to the persistent inflammation, 
the risk of cardiovascular events is increased (12). Psoria-
sis can involve the skin, joints, nails and cardiovascular 
system, and causes a significant impairment in quality 
of life amongst patients and cohabitants (13).
Several studies have investigated the overall effects of 
psoriasis on patient’s health, as well as the overall effi-
cacy of treatment. The causality of smoking and negative 
influence on health is better established in diseases other 
than psoriasis. In rheumatoid arthritis, negative associa-
tions have been shown between smoking and treatment 
response (14) and continuation of TNF blockers (15, 
16). Worse responses have been shown for methotrexate 
(MTX) treatment (17). It could therefore be assumed that 
increased TNF-α due to smoking aggravates psoriasis and 
impairs treatment response. This has been investigated 
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in spondylarthritis (18), coronary heart disease (19), he-
patocellular carcinoma (HCC) (20), non-alcoholic fatty 
liver disease (NAFLD) (21) and asthma (22).
We questioned whether smoking plays not only a 
causative role in the triggering of psoriasis, but also in 
impaired treatment success. The best evidence availa-
ble is for TNF-α. Cigarette smoking appears to have 
a synergistic effect on the secretion of inflammatory 
cytokines, such as interleukin (IL)-1 beta and TNF-α by 
macrophages (23). T-lymphocyte-released TNF-α has 
been shown to be higher in smokers and to be correlated 
with the number of pack years. Even in semen TNF-α 
levels are higher in smokers (24). In addition, C-reactive 
protein, a major inflammatory marker, is increased at a 
higher age, and among smokers (25). One study found 
higher soluble TNF receptors (sTNFR) in the serum of 
smokers, although increased serum TNF-α levels were 
not found (26). Nonetheless, other studies have clearly 
shown a correlation between increased serum levels of 
TNF-α and tobacco consumption (27, 28). Interestingly, 
not only the current smoking status, but also the dura-
tion of smoking (pack years), correlates with the level 
of serum TNF-α (27). Increased levels of serum TNF-α 
due to tobacco smoking have also been reported to cause 
an imbalance of pro- and anti-inflammatory cytokines in 
favour of pro-inflammatory cytokines (28).
For patients with psoriasis, decreased therapy response 
to ustekinumab has been shown among smokers (29).
There is no clinical data on the influence of smoking 
on IL-17 antagonists. However, IL-17 was found to be 
increased in smokers in lung tissue (30). No studies were 
found investigating the effect of smoking on the response 
of psoriasis to therapy with ciclosporin, fumaric acid 
esters, acitretin, or apremilast.
The aim of this study was to evaluate whether there 
is clinical evidence, as assessed from psoriasis registry 
data, that smoking alters the response of psoriasis to 
systemic therapies.
METHODS
After signing an informed consent, patients with moderate to 
severe psoriasis who initiated a new systemic treatment (non-
biologic as well as biologic) were included in the national non-
interventional psoriasis registries PsoBest (German Psoriasis 
Register) and SDNTT (Swiss Dermatology Network for Targeted 
Therapies), which started in December 2007 and October 2011, 
respectively. Baseline data for both registries has been published 
previously (31, 32). Both registries following the European con-
sensus in the PsoNet network (33–34), are harmonized with other 
registries on psoriasis and are registered with ClinicalTrials.gov 
(PsoBest: NCT01848028, SDNTT: NCT01706692).
PsoBest collects data from approximately 800 dermatological 
offices and outpatient clinics. Eight clinics are participating in 
SDNTT. Patients were followed-up every 3–6 months for a period 
of up to 10 years using a standardized case report form (CRF) 
completed by the physician and the patient (Fig. 1). 
Patients were asked whether they smoked. If they did, they were 
asked to specify the amount of cigarettes, cigars, cigarillos, and 
pipes they smoked. Participants also stated whether they smoked 
previously for at least one year. Smoking status was re-assessed 
after one year. Patients stated whether they had a family medical 
history of psoriasis (first degree). Physicians obtained data regar-
ding patient characteristics, e.g. age, sex, height, weight, waist-hip 
ratio, as well as disease severity (e.g. Psoriasis Area and Severity 
Index (PASI), body surface area (BSA)), which was also evaluated 
by patients (Dermatology Life Quality Index (DLQI)). Activity 
of psoriatic arthritis (PsA), and pain due to PsA was obtained 
through the physician’s CRF, using a visual analogue scale (VAS 
0–10 = no to maximum severity). In the same way, patients rated 
the pain of the PsA, as well as their psoriasis activity, using a VAS. 
Therapy response was defined as reaching a PASI reduction of 
75% (PASI 75) or PASI ≤ 3 or DLQI ≤1, taking into account not 
only relative and absolute clinical parameters, but also patient-
reported outcomes. Due to missing values in PASI, calculation of 
the relative reduction in PASI is not possible in some cases. These 
were handled with the remaining response criteria only.
Only those patients who had been treated with a systemic medi-
cation for at least one year were included in the current analysis. 
The number of patients therefore decreased over time, since 
patients were not yet observed at the time of database cut-off or 
due to treatment cessation (as-observed analyses). Patients who 
had stopped or started smoking within the last year, were also 
excluded from the analysis. In addition, data for participants who 
were observed less than one year before the database cut-off for 
our analysis (December 2016) were not included. 
The cohort encompasses all patients who were documented in 
the 2 registries (PsoBest, SDNTT) until 31 December 2016. Due 
to this cut-off date, no data for biosimilars were included.
For statistical analyses, patients were classified into subgroups: 
smokers, i.e. patients who smoked at baseline and throughout the 
first year of observation; and non-smokers, i.e. patients who did 
not smoke at baseline and did not start smoking within the first 
year of observation. Patients who changed their smoking behaviour 
within the first year of observation (onset or cessation of smoking) 
or who did not made statements on smoking, were excluded from 
analyses. For outcome analyses, patients had to be undergoing an 
ongoing treatment at the measurement time-point (as at inclusion). 
Visits in which patients had already stopped their treatment were 
excluded. The number of cases remaining is given for different 
time-points and treatments.
Descriptive analyses were performed using standard statistical 
measures (absolute and relative frequencies, means, SDs). For 
comparison of subgroups analysis of variance (ANOVA) and 
χ2 tests were used, depending on the underlying measure and 
distribution.
Start End
Months 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 87 90 93 96 99 102 105 108 111 114 117 120
Years 1 2 3 4 5 6 7 8 9 10
Time of Analysis Study Visit Specialist Visit
Fig. 1. Timeline of studies (German Psorisis Register (PsoBest) and Swiss Dermatology Network for Targeted Therapies (SDNTT)). Study 
visits were performed at the start of study and at month 3. From 6 months onwards, study visits were performed every 6 months. Regardless of study 
participation, the patients were seen by a dermatologist every 3 months (either study visit or specialist visit). During the visits Psoriasis Area and Severity 
Index (PASI), Dermatology Life Quality Index (DLQI) and Nail Psoriasis Severity Index (NAPSI) were performed. The period of analysis encompassed 
the first 12 months.
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RESULTS
Out of 5,346 patients included in the psoriasis registries, 
1,264 met the inclusion criteria and their data were analy-
sed. Of these, 423 patients were assigned to the subgroup 
“non-smokers” and 841 to the subgroup “smokers”, with 
a mean of 18.5 ± 14.0 pack years (Fig. 2).
On average, non-smokers were older than active smo-
kers (44.6 vs. 47.7, p ≤ 0.001). At baseline, the average 
patient was overweight (mean BMI 28.4 ± SD 5.9 kg/m2). 
There was no significant difference between smokers 
(27.8 ± 5.8  kg/m2) and non-smokers (28.3 ± 5.7 kg/m2; 
p ≤ 0.197) regarding BMI. Among smokers 43.5% were 
female, of all non-smokers 44.0% (p ≤ 0.879). The waist-
hip ratio was significantly lower among non-smokers 
(0.921 vs. 0.933; p ≤ 0.048). There was no difference in 
burden of therapy (p ≤ 0.214), meaning patients did not 
experience the application of treatment as a reduction in 
quality of life. The family medical history was positive 
for psoriasis in 37.8% of smokers and 37.1% of non-
smokers, yielding no significant difference (p ≤ 0.560). 
At baseline, the PASI in the active smoker cohort 
was slightly higher than in non-smokers (14.8 vs. 13.4, 
p ≤ 0.021). BSA was, however, no different (p ≤ 0.610). 
When patients self-assessed their disease severity on a 
0–10 VAS, active smokers classify their severity slightly 
but significantly higher than non-smokers (6.6 vs. 6.3 
p ≤ 0.017). Nail psoriasis (58.4 vs. 43.7, p ≤ 0.001) occur-
red more often in the group consuming tobacco and the 
number of involved nails in patients with nail psoriasis 
was higher (7.4 vs. 5.3, p ≤ 0.001). Nevertheless, PsA was 
found more frequently in non-smokers (24.1%) than in 
Fig. 2. Study enrolment. Patient inclusion and exclusion flow diagram. 
*The number of patients decreased over time, since patients were not yet 
observed at the time of database cut-off or due to treatment cessation 
(as-observed analyses). PsoBest: German Psoriasis Register; SDNTT: Swiss 
Dermatology Network for Targeted Therapies.
Patients included in the 
PsoBest - & SDNTT – registry 
(n =5,346) 
Excluded (n=4,082)  
• former smokers  
• patients who started/stopped  
smoking within first year of  
observation  
• inclusion into the registry 
within the last year  
Eligable for analyses  
(n=1,264)  
Allocated to the smoking group 
(n=841)  
Allocated to non-smoking group 
 (n=423)
Follow-up data available* 
3 months (n=715) 
6 months (n=659)  
12 months (n=504)  
 
Analysis of smoking group 
Follow-up data available*
3 months (n=358)
6 months (n=330)  
12 months (n=272)  
  
Analysis of non-smoking group 
Table I. Baseline characteristics. Baseline demographic and clinical characteristics of smokers and non-smokers (German Psoriasis 
Register (PsoBest) and Swiss Dermatology Network for Targeted Therapies (SDNTT)) and comparison statistics using a one-way analysis 
of variance (ANOVA)/χ2 test
Baseline characteristics
Smokers Non-smokers
p-valuen Mean ± SD % n Mean ± SD %
Age, years 841 44.6 ± 12.3 423 47.7 ± 16.0 0.001
Weight, kg 840 83.6 ± 19.6 420 84.0 ± 19.1 0.720
Body mass index, kg/m² 840 27.8 ± 5.8 420 28.3 ± 5.7 0.197
Sex (female) 841 43.5 423 44.0 0.879
Waist-hip ratio 770 0.9  ±  0.1 394 0.9 ±  0.1 0.048
Smoking, pack-years 771 18.5 ± 14.0 NA NA
Burden of therapy     0.214
Not at all 217 25.8 81 19.1
Somewhat 154 18.3 101 23.9
Moderately 139 16.5 79 18.7
Quite 153 18.2 87 20.6
Very 129 15.3 64 15.1
No information   49   5.8 11   2.6
Family medical history 812 37.8 410 36.1 0.560
Psoriasis Area and Severity Index (PASI) 825 14.8 ± 10.1 418 13.4 ± 9.4 0.021
Body surface area (BSA) 828 22.4 ± 19.7 416 21.8 ± 20.2 0.610
Severity of psoriasis (patient assessment) 817 6.6 ± 2.4 421 6.3 ± 2.4 0.017
Nail psoriasis 841 58 423 44 0.001
Number of involved nails 464 7.4 ± 3.2 174 5.3 ± 3.3 0.001
Psoriatic arthritis (PsA) 841 18 423 24.1 0.010
Activity PsA (physician assessment) 138 4.7 ± 2.9 98 4.1 ± 2.8 0.125
Pain PsA (patient assessment) 137 5.0 ± 2.7 93 4.3 ± 2.7 0.087
Activity PsA (patient assessment) 104 4.9 ± 2.7 79 4.2 ± 2.5 0.080
Clinical type of psoriasis
Plaque type 841 11.1 423 21.3 0.101
Small spot 841 0.6 423 1.4 0.352
Erythrodermic psoriasis 841 0.1 423 0.2 0.266
Psoriasis inversa 841 0.0 423 0.0 0.996
Psoriasis pustulosa 841 0.0 423 0.2 0.756
SD: standard deviation. Significant values are shown in bold.
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smokers (18%; p ≤ 0.010). Physician assessments showed 
no differences between smokers and non-smokers. This 
was true for activity of PsA (p ≤ 0.125) and pain in PsA 
(p ≤ 0.087). Also, patients did not assess a difference in 
PsA when they had to rate the activity (p ≤ 0.080). There 
was no difference in psoriasis type (Table I).
The majority of registered patients had received fuma-
ric acid esters at baseline (n = 1,832, 48.9%), followed 
by methotrexate (n = 1,467, 34.3%). The most frequently 
used biological agent was adalimumab (n = 564, 10.5%) 
(Fig. 3).
Response to treatment was considered to be achieved 
when PASI 75, or PASI ≤ 3 or DLQI ≤ 1 was reached. 
Overall, there was no significant difference observed 
in treatment response of skin lesions in active smokers 
compared with non-smokers when comparing for each 
individual systemic therapy after 3, 6 or 12 months (Fig. 
4A). In the smoking group, 60.6% of patients (n = 715) 
reached therapy response at month 3 compared with 
63.7% (n = 358) in the non-smoking group (p ≤ 0.269) 
(Fig. 4B). At month 6, 74.1% (n = 659) compared with 
77% (n = 330) reached PASI 75, or PASI ≤ 3 or DLQI ≤ 1 
(p ≤ 0.097) (Fig. 4C). After one year of treatment 76.6% 
(n = 504) in the smoking cohort and 79.0% (n = 272) of 
non-smokers reached treatment response (Fig. 4D). Also, 
at this time-point, this was not significant (p ≤ 0.611).
Regarding adalimumab, out of all patients it was pos-
sible to obtain valid data on response in 159 cases at 
month 3. Out of these, 116 patients responded to treat-
ment at that time. While the current smoker group showed 
a treatment response in 72.3% (n = 101) of cases, in the 
non-smoking group 74.1% (n = 58) of patient reached 
this goal (p ≤ 0.799) after 3 months. Neither was there 
any difference in treatment response at month 6 (data 
for 156 patients were analysed, of which a response was 
seen in 78.0% (n = 100) vs. 76.8% (n = 56) (p ≤ 0.862)) 
or month 12 (data for 111 participants were analysed, 
78.6% (n = 70) vs. 87.8% (n = 41) (p ≤ 0.222)) between 
the 2 groups of patients receiving adalimumab.
For etanercept, valid data on response were received 
for 77 patients at month 3. In the smoking group 50.0% 
(n = 50) were considered to have achieved either PASI 
75 or PASI ≤ 3 or DLQI ≤ 1. In comparison, 70.4% 
(n = 27) of non-smokers had a therapy response after 3 
months of treatment. However, this difference was not 
significant (p ≤ 0.085). Also, after 6 (70.5% (n = 54) vs. 
Fig. 3. Number of patients included in the registry by baseline 
treatment, subgrouped as current smokers and non-smokers. 
ADA: adalimumab; ETN: etanercept; IFN: infliximab; UST: ustekinumab; 
SEC: secukinumab; APR: apremilast; FAE: fumaric acid esters; MTX: 
methotrexate; CSA: ciclosporin; RET: retinoids.
Fig. 4. Non-smokers, current smokers and both groups combined 
(total) who reached treatment response. (A) By smoking status, defined 
as reaching a Psoriasis Area and Severity Index (PASI) reduction of 75% (PASI 
75) or PASI ≤3 or DLQI ≤1, at 3, 6 and 12 months of ongoing treatment. 
(B) At month 3. (C) At month 6. (D) At month 12. ADA: adalimumab; ETN: 
etanercept; IFN: infliximab; UST: ustekinumab; SEC: secukinumab; APR: 
apremilast; FAE: fumaric acid esters; MTX: methotrexate; CSA: ciclosporin; 
RET: retinoids.
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76.7% (n = 30), p ≤ 0.555) and 12 months (75.9% (n = 29) 
vs. 84.0% (n = 25), p ≤ 0.459) there was no significant 
difference between the 2 groups.
In 24 cases, valid data on response were obtained 
for patients on infliximab (64.3% (n = 14) vs. 80.0% 
(n = 10), p ≤ 0.404) at month 3. Also, at later time-points 
(months 6 and 12), no difference was found in achieving 
response to treatment between the smoking group vs. the 
non-smokers (70.0% (n = 10) vs. 85.7% (n = 7), p ≤ 0.452; 
100.0% (n = 8) vs. 80.0% (n = 5), p ≤ 0.188).
For ustekinumab, the data for 104 patients were valid 
for response evaluation at month 3. Of these patients 
78.1% (n = 73) (smokers) vs. 67.7% (n = 31) (non-smo-
kers) (p ≤ 0.265) responded to treatment. Also, at month 6 
(88.9% (n = 72) vs. 82.1% (n = 28), p ≤ 0.368) and month 
12 (80.4% (n = 56) vs. 81.0% (n = 21), p ≤ 0.953), one year 
after initiation of treatment, no statistical difference in 
response rate was seen between the 2 groups.
Regarding secukinumab and apremilast, which, at 
the time of data cut-off, were the newer drugs in anti-
psoriatic treatment, not enough valid response data could 
be obtained for any statistical comparison of smokers 
(valid n = 0 and n = 1, respectively) and non-smokers 
(valid n = 2 and n = 0, respectively). 
For fumaric acid esters, data for 327 patients at month 
3 were obtained. 43.0% (n = 207) of smokers responded 
to treatment, while 53.3% (n = 120) of non-smokers 
did (p ≤ 0.071). At month 6 (66.7% (n = 192) vs. 74.8% 
(n = 111), p ≤ 0.139) and month 12 (74.4% (n = 160) vs. 
76.3% (n = 97), p ≤ 0.731) there was also no difference 
between smokers and non-smokers.
The data on methotrexate did not yield any signifi-
cant differences between smokers and non-smokers at 
month 3 (67.0% (n = 206) vs. 64.6% (n = 82), p ≤ 0.703), 
6 (75.4% (n = 191) vs. 76.7% (n = 73), p ≤ 0.823) or 12 
(76.6% (n = 145) vs. 73.1% (n = 67), p ≤ 0.963). 
For ciclosporin there was no statistical difference 
between treatments group at month 3 (62.5% (n = 48) vs. 
61.9% (n = 21), p ≤ 0.963), 6 (73.0% (n = 37) vs. 77.8% 
(n = 18), p ≤ 0.701) or 12 (72.7% (n = 22) vs. 84.6% 
(n = 13), p ≤ 0.418).
Data for only 22 patients were valid concerning the 
response to retinoids at month 3. While 73.3% (n = 15) of 
the smoking group responded to treatment, 85.7% (n = 7) 
(p ≤ 0.519) of the non-smokers did. No statistically dif-
ferent results between the groups were seen at month 6 
(66.7% (n = 12) vs. 100.0% (n = 5), p ≤ 0.140) or at month 
12 (69.2% (n = 13) vs. 100.0% (n = 3), p ≤ 0.267).
After 12 months the number of patients continuing 
their treatment was 111 (70 smokers and 41 non-smokers) 
for adalimumab, 54 (29/25) for etanercept, 12 (8/4) for 
infliximab, 77 (56/21) for ustekinumab, 0 for secukinu-
mab, 1 smoker for apremilast, 257 (160/97) for fumaric 
acid esters, 212 (145/67) for methotrexate, 35 (22/13) 
for ciclosporin A, 16 (13/3) for retinoids, an overall total 
of 776 (504/272). 
Overall, there was no significant difference between 
smokers and non-smokers regarding any treatment at 
any time-point.
DISCUSSION
The data from the cohort of patients with psoriasis for 
Germany and Switzerland analysed prospectively in 
this study confirms the results of previous prospective 
(35–37) and retrospective (38–40) studies, in demonstrat-
ing that active smoking does not significantly affect the 
treatment response of skin lesions in psoriasis to systemic 
therapies. Menter et al. reported the absence of a correla-
tion between active tobacco use and PASI 75 response in 
a prospective study with 814 patients treated with adalim-
umab (35). Similar results were reported in a prospective 
study with 2,368 patients, where smoking was shown not 
to affect treatment response, whereas BMI significantly 
decreased the response to systemic anti-psoriatic treat-
ment (36). In contrast, a retrospective report by Rakkhit 
et al. (40) detected a minimally superior response of 
psoriasis to etanercept in non-smokers compared with 
active smokers. No difference between smoking status 
and efficacy of TNF-α blockers and ustekinumab was, 
however, found in a retrospective Italian study of 350 pa-
tients (39). A smaller retrospective study yielded similar 
results; however, only 36 non-smokers and 20 smokers 
met the inclusion criteria (38). 
Interestingly, in a prospective study with 434 inflam-
matory bowel disease patients treated with TNF-anta-
gonists, almost 5% developed a paradoxical psoriasis. 
Smoking was shown to be an important risk factor, and all 
of these patients had cutaneous infiltrates with increased 
numbers of IL-17A/ IL-22-secreting T helper cells (37).
The published data to date is thus not homogeneous. 
In a retrospective study with 110 patients with psoriasis 
treated with TNF antagonists, 13 non-responders were 
assessed in detail, and a history of active smoking at 
the onset of therapy appeared to be associated with 
non-response. The majority (61.5%, n = 8; OR: 2.71 
(0.82–8.92) of non-responders were smokers (41). No 
data on p-values were published.
There was a difference in age between our 2 cohorts. 
Smokers tended to be younger than non-smokers, 
leading to speculation about how much this affects tre-
atment outcome. Our data also indicated that PsA was 
significantly less frequent in active smokers compared 
with non-smokers. In a published large study consisting 
of 1,388 patients it was reported that active smokers 
not only had a poorer treatment response, but also had 
worse treatment adherence. Interestingly, active smokers 
were less affected by obesity, had a shorter duration of 
disease, and the affected joint count was lower than in 
non-smokers. However, they scored more points on the 
visual analogue scale (VAS) than the comparison group 
at baseline. Once treated, the reduction in pain was not 
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statistically different between smokers and non-smokers 
(42). 
In total, non-smokers had better starting conditions, as 
their PASI was lower (13.4) compared with that of smo-
kers (14.8). Also, self-assessed severity and nail psoriasis 
were more severe in the cohort of smokers. This has 
been reported previously and was also true in our study.
In certain other diseases, such as axial spondylarthritis, 
the effect of tobacco consumption on therapy response 
has also been analysed. A decreased response to TNF-
antagonist treatment was reported in smokers with axial 
spondylarthritis (18). This was especially true for active 
smokers compared with non-smokers. 
Recently, a multicentre, observational, prospective 
pharmacovigilance study (BADBIR), identified factors 
associated with a higher likelihood of achieving PASI 90 
in biologic-naïve patients. Among other factors, smoking, 
or even only having a history of smoking, was associa-
ted with a reduced probability of treatment response in 
patients on biologic therapy (43). The study included 
more patients (n = 3,079 at 6 months and n = 3,110 at 
12 months), which might be an explanation for the dif-
ference in results.
Since only 1,264 patients could be selected for ana-
lysis there is a potential selection bias in our study, 
which may be a weakness. Possible differences in the 
resonance rates in the treatment groups may not have 
been detected due to the small number of cases in the 
subgroups and the resulting insufficient power. However, 
a power calculation (90% power, 5% alpha, 10% equi-
valence limit, 50% response rate) was performed and, 
assuming there was no difference between the smokers 
and non-smokers regarding treatment response, 1,084 
patients would be required. There were some differences 
at baseline such  as age, PASI, psoriasis severity (patient 
assessment), nail psoriasis, number of involved nails and 
the presence of PsA. This could be a potential bias, but 
it is expected to be small, since we considered absolute 
and relative measures for treatment response. Also, PsA 
was not evaluated by a rheumatologist, and none of the 
usual scores were utilized. In registry studies there is no 
control for confounding, which poses a limitation to this 
work. Comparisons of the effect of smoking on response 
by treatment are not powered sufficiently to detect dif-
ferences, and therefore the results should be interpreted 
in the light of this knowledge. One important limita-
tion of this study was that difference in response given 
smoking status was contingent on the patient remaining 
on treatment until the relevant time-period. The high 
number of smokers in our cohort can be explained by 
the fact that former smokers (and current non-smokers) 
were excluded from the analysis. 
In conclusion, this prospectively collected registry-
based data analysis of 1,264 patients did not show that 
smoking affects the response of psoriasis skin lesions to 
systemic therapy.
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